Huerta NI, López SK, Zazueta PJF, Santiago JG, Hernández CA

Language: Spanish
References: 16
Page: 1-7
PDF size: 441.96 Kb.

ABSTRACT

BACKGROUND: Mycosis fungoides is the most common extranodal non-Hodgkin T-cell lymphoma. Clinically it begins with erythematous macules or plaques, progressing to advanced stages with tumor lesions or its leukemic variant in 20% of cases.
CLINICAL CASE: A 52-year-old male patient with generalized dermatosis of 7 years’ duration, characterized by multiple neoformations, intense pruritus and exacerbations during the past year. After multiple medical treatments without relieve of the lesions, the patient was referred to the General Hospital of Mexico Dr. Eduardo Liceaga, where a diagnostic protocol was initiated, leading to the diagnosis of cutaneous T-cell non- Hodgkin lymphoma of the mycosis fungoides type.
CONCLUSIONS: Mycosis fungoide remains an underdiagnosed disease, which impacts patient survival. Early diagnosis and proper management are crucial to ensuring effective treatment.

REFERENCES

1. Huang J, Chan SC, Lok V, et al. Global burden, risk factors,and trends of non-Hodgkin lymphoma: A worldwide analysisof cancer registries. Cancer Med 2024; 13 (5): e7056.https://doi.org/10.1002/cam4.7056

2. Miyashiro D, Sanches JA. Mycosis fungoides and Sézarysyndrome: clinical presentation, diagnosis, staging, andtherapeutic management. Front Oncol 2023; 13: 1141108.https://doi.org/10.3389/fonc.2023.1141108

3. Pérez HC, Morales S, Enciso L, et al. Folliculotropic mycosisfungoides in a Latin American hospital: Survival analysis.Actas Dermosifiliogr 2022; 113 (10): 930-937. https://doi.org/10.1016/j.ad.2022.07.018

4. Muñoz-González H, Molina-Ruiz AM, Requena L. Clinicopathologicvariants of mycosis fungoides. Actas Dermosifiliogr2017; 108 (3): 192-208. https://doi.org/10.1016/j.ad.2016.08.009

5. Bahalı AG, Su O, Cengiz FP, et al. Prognostic factors ofpatients with mycosis fungoides. Postepy DermatolAlergol 2020; 37 (5): 796-799. https://doi.org/10.5114/ada.2020.100491

6. Pujol RM, Gallardo F. Cutaneous lymphomas. Part I: mycosisfungoides, Sézary syndrome, and CD30-positive cutaneouslymphoid proliferations. Actas Dermosifiliogr 2021; 112 (1):14-23. https://doi.org/10.1016/j.ad.2020.08.003

7. Lee H. Mycosis fungoides and Sézary syndrome. BloodRes 2023; 58 (S1): 66-82. https://doi.org/10.5045/br.2023.2023023

8. Weiner DM, Rook AH. Cutaneous T-cell lymphoma. HematolOncol Clin North Am 2024; 38 (5): 1087-1110. https://doi.org/10.1016/j.hoc.2024.05.012

9. Vaidya T, Badri T. Mycosis fungoides. En: StatPearls. TreasureIsland (FL): StatPearls Publishing; 2025.

10. Schukow C, Ahmed A. Dermatopathology, cutaneouslymphomas. En: StatPearls. Treasure Island (FL): StatPearlsPublishing; 2025.

11. Hodak E, Amitay-Laish I. Mycosis fungoides: A great imitator.Clin Dermatol 2019; 37 (3): 255-267. https://doi.org/10.1016/j.clindermatol.2019.01.004

12. Hague C, Farquharson N, Menasce L, et al. CutaneousT-cell lymphoma: diagnosing subtypes and the challenges.Br J Hosp Med (Lond) 2022; 83 (4): 1-7. https://doi.org/10.12968/hmed.2021.0149

13. Hristov AC, Tejasvi T, Wilcox RA. Cutaneous T-cell lymphomas:2023 update on diagnosis, risk-stratification, andmanagement. Am J Hematol 2023; 98 (1): 193-209. https://doi.org/10.1002/ajh.26760

14. Miyagaki T. Diagnosis and prognostic stratification ofcutaneous lymphoma. J Dermatol 2022; 49 (2): 210-222.https://doi.org/10.1111/1346-8138.16099

15. Scarisbrick JJ. Survival in mycosis fungoides and Sezarysyndrome: How can we predict outcome? J Invest Dermatol2020; 140 (2): 281-283. https://doi.org/10.1016/j.jid.2019.08.440

16. Hague C, Farquharson N, Menasce L, et al. Cutaneous T-celllymphoma: subtype diagnosis and the challenges. Br J HospMed (London, England: 2005) 2022; 83 (4): 1-7. https://doi.org/10.12968/hmed.2021.0149